# 2026-09543: FDA Asks for Input on Post-Market Drug Safety Reporting

2026-09543, Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-13, effective 2026-10-01; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-09543
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-09543
- Title: Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 27065
- Published: 2026-05-13
- Effective: 2026-10-01
- Comments close: 2026-07-13
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Asks for Input on Post-Market Drug Safety Reporting

## Summary

The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on postmarketing reporting and recordkeeping of adverse experiences for drug and biological products.

## Effects PRIA read

- Mandatory ICH E2B(R3) Data Standard: cost, medium. If you submit postmarketing individual case safety reports (ICSRs) via FDA's Electronic Submissions Gateway Next Generation (ESG NextGen), those ICSRs must use the ICH E2B(R3) data standards beginning October 1, 2026. FDA began accepting E2B(R3) voluntarily in January 2024 and is now requiring the…
- 10- and 6-Year Recordkeeping Rules: cost, medium. Applicants and manufacturers must keep adverse drug experience records for 10 years under 21 CFR 314.80(j) and 310.305(g). For nonprescription human drug products under section 760(e), responsible persons must retain nonprescription adverse event records for 6 years.
- Periodic Report Timing Requirement: cost, low. For approved drug applications, periodic postmarketing safety reports must be submitted quarterly for the first 3 years after U.S. approval and annually thereafter, per 21 CFR 314.80(c)(2) and 600.80(c)(2). These reports must include narratives, summaries, analyses, and indexes of adverse experienc…
- 5-Day Combination-Product Notification Rule: cost, low. If a combination product event involves a drug and a constituent applicant receives information about a death, serious injury, or adverse event, that information must be provided to other constituent part applicants no later than 5 calendar days after receipt under 21 CFR 4.103. Rules for submissio…
- Enhanced Pharmacovigilance Requests by FDA: cost, medium. FDA's January 2024 'Best Practices' may lead to enhanced pharmacovigilance activities for specific products; FDA may request use of targeted data collection tools, expedited submission of adverse experiences beyond minimum reporting, and summarization/assessment at FDA-defined frequencies. FDA has…
- Electronic Submission Waivers for Good Cause: benefit, low. All reports and followup reports generally must be submitted electronically, but FDA may grant temporary waivers of the electronic submission requirements for good cause. Waiver requests can be submitted under the cited regulations.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-09543 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/13/2026-09543/agency-information-collection-activities-proposed-collection-comment-request-postmarketing-adverse)
- [2026-09543 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-13/pdf/2026-09543.pdf)

## Related
- [Previous: 2026-09542, Agency Information Collection Activity Under OMB Review: Staff Sergeant Parker…](https://policyrisk.com/federal-register/2026-09542)
- [Next: 2026-09544, Modified Risk Tobacco Product Application: Renewal Applications for VLN® King a…](https://policyrisk.com/federal-register/2026-09544)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-09543 (as of 2026-06-08).
